EU industry responds to Lalis' letter and latest MDD (Medical Devices Directive) review text
This article was originally published in Clinica
Eucomed, the European medical technology industry association, is disappointed that many of the issues that it has flagged as priorities in the context of the review of the Medical Devices Directive (MDD) have seemingly not been taken up by the Commission in the latest text of the proposed review. Although this text had still not been published as Clinica went to press, Commission director, Georgette Lalis, who oversees medical device legislation, has recently written a letter to those who responded to the public consultation on the review concerning the outcome of that consultation.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.